4Lipsky BA, Itani K, Norden C. Treating foot infections in dia.betic patients: a randomized, multicenter, open - label trial of linezolid versus ampicillin - sulbactam/co - amoxiclav. Clinical Infectious Diseases 2004;38 : 17 - 24.
5Lavery LA, Baranoski S, Ayello EA. Options for off - loadingthe diabetic foot. Advances in Skin & Wound Care 2004 : 17(4) : 181- 186.
6Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off- loading the diabetic foot wound: a randomized clinical trial. Diabetes Care 2001;24:1019 - 1022. Erratum in:Diabetes Care 2001 ;24:1509.
7Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24:290 -295.
5American diabetes association.Report of the expert committee on the diagnosis and classification of diabetes mellitus.Diabetes care,1997,20:1183
6Tomaru T,Uchida Y,Nakamura F,et al.Enhencement of arterial thrombolysis with native t-PA by pretreatment with heparin or batroxobin:An angioscopic study.Am heart J,1989,117:275
7Boulton A J. The diabetic foot: a global view[J]. Diabetes Metab Res Rev,2000,16(suppl 1):S2-S5.
8Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot?[J]. Diabetes Metab Res Rev,2000,16:S75-S83.
9Lavery L A, Armstrong D G, Harkless L B. Classification of diabetic foot wounds[J]. J Foot Ankle Surg,1996,35:528-531.
10Pham H, Armstrong D G, Harvey C, et al. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial[J]. Diabetes Care,2000,23:606-611.
